Neuphoria Therapeutics Inc. Operating Cash Flow
Neuphoria Therapeutics Inc. (NEUP) reported Operating Cash Flow of -$12.35 million for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-18.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-09-18
- Neuphoria Therapeutics Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was $1.21M.
- Neuphoria Therapeutics Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$3.34M, a 129.13% decline year-over-year.
- Neuphoria Therapeutics Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$6.44M.
- Neuphoria Therapeutics Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$3.79M.
- Neuphoria Therapeutics Inc. net cash provided by (used in) operating activities for fiscal 2026 was -$12.35M, a 16095.38% decline from fiscal 2025.
- Neuphoria Therapeutics Inc. net cash provided by (used in) operating activities for fiscal 2025 was $77.23K.
- Neuphoria Therapeutics Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$14.68M.
- Neuphoria Therapeutics Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$14.64M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-18 | -$2.12M derived: sum of 2 quarters · filed 2026-09-18 | -$8.56M derived: sum of 3 quarters · filed 2026-09-18 | -$12.35M 10-K · filed 2026-09-18 |
| 2026-03-31 | -$3.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-15 | -$9.77M derived: sum of 2 quarters · filed 2026-05-15 | -$13.57M 10-Q · filed 2026-05-15 | -$17.15M derived: sum of 4 quarters · filed 2026-09-18 |
| 2025-12-31 | -$6.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-17 | -$10.23M 10-Q · filed 2026-02-17 | -$13.82M derived: sum of 3 quarters · filed 2026-09-18 | -$2.36M derived: sum of 4 quarters · filed 2026-09-18 |
| 2025-09-30 | -$3.79M 10-Q · filed 2025-11-14 | -$7.38M derived: sum of 2 quarters · filed 2026-09-18 | $4.07M derived: sum of 3 quarters · filed 2026-09-18 | $715.64K derived: sum of 4 quarters · filed 2026-09-18 |
| 2025-06-30 | -$3.59M derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-18 | $7.87M derived: sum of 2 quarters · filed 2026-09-18 | $4.51M derived: sum of 3 quarters · filed 2026-09-18 | $77.23K 10-K · filed 2026-09-18 |
| 2025-03-31 | $11.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-15 | $8.10M derived: sum of 2 quarters · filed 2026-05-15 | $3.66M 10-Q · filed 2026-05-15 | $651.51K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | -$3.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-17 | -$7.79M 10-Q · filed 2026-02-17 | -$10.80M derived: sum of 3 quarters · filed 2026-02-17 | -$14.10M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-09-30 | -$4.43M 10-Q · filed 2025-11-14 | -$7.44M derived: sum of 2 quarters · filed 2025-11-14 | -$10.74M derived: sum of 3 quarters · filed 2025-11-14 | -$14.68M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | -$3.01M derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-29 | -$6.31M derived: sum of 2 quarters · filed 2025-09-29 | -$10.25M derived: sum of 3 quarters · filed 2025-09-29 | -$14.68M 10-K · filed 2025-09-29 |
| 2024-03-31 | -$3.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-20 | -$7.24M derived: sum of 2 quarters · filed 2025-05-20 | -$11.67M 10-Q · filed 2025-05-20 | |
| 2023-12-31 | -$3.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-02-14 | -$8.37M 10-Q · filed 2025-02-14 | ||
| 2023-09-30 | -$4.43M 10-Q · filed 2024-11-14 | |||
| 2023-06-30 | -$14.64M 10-K · filed 2024-09-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |